These 2 Shocking Stocks Have Outperformed the S&P in 2020 -- by a Lot

Despite a rough start to the year due to COVID-19, the S&P 500 has bounced back nicely since hitting a low point in March. In fact, this closely watched stock index is currently up by a respectable 8.6% for the year.

The S&P 500's fairly strong performance in 2020, however, is nothing compared to that of the clinical-stage biotechs Novavax (NASDAQ: NVAX) and Vaxart (NASDAQ: VXRT). At one point this year, Novavax's shares were up by an astonishing 4,500%, and Vaxart's stock jumped by a rip-roaring 4,680% at its high-water mark in 2020.

Image source: Getty Images.

Source Fool.com